| Revenue FY26 | ₹814.2 Cr19.5% YoY Growth |
|---|---|
| Market Cap | ₹12,431 CrHealthcare Services |
| EBITDA Margin | 41.4%Full Year FY26 |
| RSI | 86.91Overbought Zone |
Key highlights
- Q4 FY26 revenue reached a record ₹2,194 million, representing a 26.6% year-on-year growth.
- Full-year FY26 revenue stood at ₹8,142 million, outperforming the company's long-term growth guidance of 15%.
- EBITDA margins for the fourth quarter hit 43.5%, contributing to an annual PAT of ₹1,730 million.
- Total test volume increased by 14.4% in FY26, while the wellness segment grew by 25.6% during the same period.
- Management announced the planned addition of 4-5 new hubs and 10-12 spoke clinics for the upcoming financial year.
Financial Performance
Vijaya Diagnostic's fiscal year 2026 was marked by robust top-line and bottom-line expansion. The company recorded its highest-ever quarterly revenue in Q4, totaling ₹2,194 million. This momentum carried through to the full year, with total revenue reaching ₹8,142 million, a 19.5% increase over the previous year.
Profitability remained strong as PAT grew 20.3% to ₹1,730 million. Operational efficiency was evident in the EBITDA margins, which settled at 41.4% for the full year, surpassing the company's internal guidance of 40%. This performance was primarily underpinned by disciplined execution and strong volume growth in both pathology and high-value radiology services.
Management Outlook
Leadership expressed high confidence in the company's trajectory, noting that the five-year CAGR of 16.5% consistently exceeds their 15% long-term guidance. Looking ahead to FY27, Vijaya plans to deepen its footprint by setting up 4-5 integrated hubs and 10-12 spoke clinics. A key strategic focus is the establishment of a fully automated laboratory in Hyderabad to enhance processing efficiency and turnaround times.
Furthermore, the company intends to launch advanced genomic testing services to diversify its diagnostic portfolio. This expansion strategy aims to balance the dominance in core Telangana markets while scaling operations in newer territories and the high-growth wellness diagnostics space.
Business Overview
Vijaya Diagnostic Centre Ltd is a prominent integrated diagnostic chain in India, particularly dominant in South India. The company offers a comprehensive suite of pathology and radiology services under one roof, which serves as a significant competitive advantage in patient retention and convenience. Its service portfolio includes over 1,500 pathology tests and 250 radiology tests.
The wellness segment has become a core growth engine, contributing significantly to the recent revenue surge as preventive healthcare adoption rises. The company continues to leverage its hub-and-spoke model to provide high-end diagnostic imaging and laboratory services across its expanding network.
Sector Dynamics
The Indian diagnostic sector is witnessing a shift towards organized players as demand for high-quality, reliable testing increases across the country. The wellness and preventive healthcare segment is growing faster than routine diagnostic services, driven by increasing health awareness. While competition remains intense with the entry of new diagnostic players and digital aggregators, integrated players like Vijaya benefit from the 'one-stop-shop' model.
Management noted that the increasing complexity of medical diagnoses is driving demand for advanced radiology and specialized pathology services. However, the industry continues to face challenges related to geographic concentration and the requirement for continuous technological upgrades to maintain competitive edges.
What to Watch
- Timely execution and operationalization of the 4-5 planned hubs and 10-12 spokes in FY27.
- The impact of the new automated Hyderabad lab on processing efficiency and overall operating margins.
- Market reception and revenue contribution from the newly introduced advanced genomic testing services.
- Success in scaling brand presence in non-core markets beyond the established Hyderabad and Telangana strongholds.
- Sustainability of EBITDA margins above the 40% threshold amidst rising competitive pressures in the diagnostic space.
“Landmark year; highest-ever quarterly revenue in Q4.”
| Share price | ₹1208.1 |
|---|---|
| Market capitalisation | ₹12,430.95 Cr |
| Revenue (annual) | ₹681.39 Cr |
| Net profit (annual) | ₹143.08 Cr |
| Revenue (latest quarter) | ₹205.21 Cr+1.81% vs previous quarter |
| Net profit (latest quarter) | ₹43.18 Cr-0.25% vs previous quarter |
| P/E (TTM) | 77.97×Sector 62.72× |
| Promoter holding | 52.51%-0.09% QoQ |
| FII holding | 13.38%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Vijaya Diagnostic Centre Ltd announcing the financial results for the quarter and year ended March 31, 2026. Market figures from a third-party data provider.
